Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

March 26, 2021

Study Completion Date

April 23, 2021

Conditions
Chemotherapy Induced Anemia
Interventions
DRUG

Roxadustat

Roxadustat will be administered per schedule specified in the arm description.

Trial Locations (15)

10469

Research Center, The Bronx

11776

Research Center, Port Jefferson Station

17325

Research Center, Gettysburg

19106

Research Center, Philadelphia

20817

Research Center, Bethesda

32256

Research Center, Jacksonville

33322

Research Center, Plantation

41101

Research Center, Ashland

44718

Research Center, Canton

46804

Research Center, Fort Wayne

70433

Research Center, Covington

90024

Research Center, Los Angeles

90505

Research Center, Torrance

90720

Research Center, Los Alamitos

07039

Research Center, Livingston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Astellas Pharma Inc

INDUSTRY

lead

FibroGen

INDUSTRY